Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
Share
Why It Matters
A stock expert named Martin Fan still thinks Zenas BioPharma will do well. He believes the stock could be worth around $45 per share based on what he sees.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.